uniQure (NASDAQ:QURE) CEO Matthew Kapusta Sells 6,696 Shares of Stock

uniQure N.V. (NASDAQ:QURE) CEO Matthew Kapusta sold 6,696 shares of uniQure stock in a transaction that occurred on Wednesday, June 24th. The shares were sold at an average price of $50.00, for a total transaction of $334,800.00. Following the sale, the chief executive officer owned 519,227 shares of the company’s stock, valued at approximately $25,961,350. The trade was a 1.27% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

uniQure Stock Performance

NASDAQ QURE traded down $1.59 on Friday, reaching $47.51. 3,154,443 shares of the company’s stock traded hands, compared to its average volume of 2,765,936. uniQure N.V. has a fifty-two week low of $8.73 and a fifty-two week high of $71.50. The company has a debt-to-equity ratio of 0.33, a quick ratio of 10.40 and a current ratio of 10.40. The firm has a market cap of $3.00 billion, a price-to-earnings ratio of -13.65 and a beta of 0.98. The stock has a 50 day moving average price of $27.23 and a 200-day moving average price of $22.85.

uniQure (NASDAQ:QURE) last released its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.03. uniQure had a negative return on equity of 145.81% and a negative net margin of 1,154.42%.The business had revenue of $3.56 million during the quarter, compared to analyst estimates of $5.21 million. Equities research analysts predict that uniQure N.V. will post -3.64 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of QURE. China Universal Asset Management Co. Ltd. boosted its holdings in uniQure by 5.5% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 10,150 shares of the biotechnology company’s stock worth $243,000 after buying an additional 533 shares during the last quarter. Arizona State Retirement System boosted its stake in shares of uniQure by 6.0% in the fourth quarter. Arizona State Retirement System now owns 11,141 shares of the biotechnology company’s stock worth $267,000 after acquiring an additional 627 shares during the last quarter. Ensign Peak Advisors Inc increased its position in shares of uniQure by 21.7% during the fourth quarter. Ensign Peak Advisors Inc now owns 3,650 shares of the biotechnology company’s stock worth $87,000 after purchasing an additional 650 shares in the last quarter. FNY Investment Advisers LLC increased its position in shares of uniQure by 76.7% during the third quarter. FNY Investment Advisers LLC now owns 1,654 shares of the biotechnology company’s stock worth $96,000 after purchasing an additional 718 shares in the last quarter. Finally, CIBC Private Wealth Group LLC purchased a new position in uniQure in the 3rd quarter valued at $50,000. Institutional investors and hedge funds own 78.83% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently issued reports on QURE shares. Royal Bank Of Canada boosted their target price on shares of uniQure from $35.00 to $65.00 and gave the company an “outperform” rating in a research note on Thursday, June 18th. Chardan Capital upped their price objective on shares of uniQure from $31.00 to $37.00 and gave the stock a “buy” rating in a research report on Thursday, April 30th. Cantor Fitzgerald upgraded uniQure from a “neutral” rating to an “overweight” rating and set a $61.00 price target for the company in a research note on Wednesday, June 17th. Stifel Nicolaus set a $28.00 price target on uniQure in a report on Tuesday, May 5th. Finally, TD Cowen reiterated a “buy” rating on shares of uniQure in a research report on Tuesday, March 3rd. Twelve analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $61.67.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno?associated viral (AAV) vector platform, the company designs single?dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.